Role Of Pramipexole In Key Research Areas Of Parkinson's Disease Management Discussed At 12th EFNS Congress

Professor Anthony Schapira, Chairman of the University Department of Clinical Neurosciences, Institute of Neurology, Queen Square, UCL, and Professor of Neurology at the National Hospital and Royal Free Hospital, London, UK and organizer den investigator inside wish of PROUD*1, presented a foreign assessment to make enquiries the slow of clinical bud in PD, a switch focus of established research in the red to this outstanding unmet obligation. Previous pramipexole study hold suggested a upcoming neuroprotective effect, such via manner of the CALM-PD** study2,3 and in vitro studies. PROUD, on the other paw, be the rash study to amalgamate measurements of clinical result in a PD tolerant aligned with measurements of dopamine owner staunchness of guaranteed brainpower zone (basal ganglia), through a SPECT imaging arm of the study.1 Commenting unwilling the study in view of that far, Professor Schapira said: "The debate on when and how to luxury early Parkinson's virus patients have be ongoing. Currently, writing would as standard be initiate when symptom have rationale disability. However, providing the medical confirmation for a treatment to retard or rule out the progression of PD is a highest invigorating priority and the PROUD study aims to radiate more hours of darkness light into this probe. Pramipexole be considered an optimal foe for this study due to evidence suggesting to be expected benefits to PD patients onwards treat the reputed essence symptoms. Based on the exceptional technique previously owned here study, PROUD may make available a major breakthrough in our analysis of early PD treatment which would submit anticipation to the ever cumulative numeral of patients diagnose with Parkinson's disease." Study grades be programmed to be at your disposal in 2009.

Pramipexole studies pursue other new avenue of research to come across treatment wants Further areas of current PD research with pramipexole are the overseeing of PD-related depressive symptoms and ongoing studies to weigh against a new formulation so as to provide physician and patients using pramipexole with an even broader treatment regimen to larger meet differing patient needs and lifestyles.4,5,6 PD-related depressive symptoms A new pramipexole study conduct in plainly 70 European nucleus aims to study management of depressive symptoms in PD patients.7 Emerging facts set forward that pramipexole may have a accepting effect on depressive symptoms and motivation associated with PD, in codicil to effectively controlling the motor symptoms of PD.8-16 The specific receptor profile of pramipexole may be culpable for the possible antidepressant property of this merged and clinical research is ongoing to find out this aspect of pramipexole's pharmacological profile in more refinement.17,18,19 Professor Paolo Barone, Department of Neurological Sciences, University of Napoli-Federico II, Naples, Italy and lead investigator of both PRODEST4 and the new European study7 said: "Previously, the PRODEST study identified that PD-related depressive symptoms are customary, with nearly partly of those PD patients unloading anti-depressants continuing to perceive depressive symptoms. These symptoms impact clearly on talent of progress, both for PD patients and their carers. The new European study aims to provide answers on the role pramipexole may cavort in managing these prevalently mature PD-related depressive symptoms that are commonly under-recognised and thus under-treated." Widening judgment of pramipexole treatment option Favourable results of pharmacokinetic period I studies with a new once day by day pramipexole common free formulation be presented at EFNS and column the escalation of this new formulation.5,6 Pramipexole is the prime dopamine agonist treatment for PD and these ongoing studies aim to advance the surviving treatment regimen with a once daily formulation to go one footfall further to scheduled time a broader go up of patients' needs.